Sonia T. Oskouei, PharmD, BCMAS, DPLA

With the FDA approval and launch of the first interchangeable biosimilar in the United States in 2021, retail pharmacists are poised to play an increasing role in the future uptake of biosimilars.

The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.